Leukemia Clinical Trial
Official title:
A Phase I Study Of Therapy With The Farnesyl Transferase Inhibitor R115777 (Zarnestra) Combined With Conventional Induction And Consolidation Chemotherapy For Previously Untreated Patients Over Age 55 With Acute Myeloid Leukemia (AML)
RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as cytarabine and daunorubicin,
work in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving tipifarnib together with cytarabine and daunorubicin may
kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of tipifarnib when
given with cytarabine and daunorubicin in treating older patients with acute myeloid
leukemia.
Status | Completed |
Enrollment | 24 |
Est. completion date | |
Est. primary completion date | March 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 56 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Diagnosis of acute myeloid leukemia (AML) - All subtypes, except acute promyelocytic leukemia, are allowed - At least 20% bone marrow or peripheral blood blasts OR biopsy-confirmed extramedullary disease - No cerebrospinal fluid involvement PATIENT CHARACTERISTICS: Age - 56 and over Performance status - ECOG 0-2 OR - Karnofsky 60-100% Life expectancy - Not specified Hematopoietic - See Disease Characteristics - WBC < 100,000/mm^3 (treatment with hydroxyurea allowed) Hepatic - Bilirubin = 1.25 times upper limit of normal (ULN) - AST and ALT = 2.0 times ULN Renal - Creatinine < 1.7 mg/dL OR - Creatinine clearance = 60 mL/min Cardiovascular - LVEF = 50% - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia Immunologic - HIV negative - No history of allergic reaction attributed to compounds of similar chemical or biologic composition to tipifarnib or imidazole drugs (e.g., ketoconazole, clotrimazole, or miconazole) - No ongoing or active infection Other - Not pregnant - Fertile patients must use effective contraception - Able to swallow oral medications - No other uncontrolled illness - No psychiatric illness or social situation that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior chemotherapy for AML except hydroxyurea for cytoreduction - More than 4 weeks since prior chemotherapy except hydroxyurea (6 weeks for nitrosoureas or mitomycin) and recovered - At least 24 hours since prior hydroxyurea Endocrine therapy - No concurrent dexamethasone Radiotherapy - More than 4 weeks since prior radiotherapy and recovered - No prior radiotherapy > 3,000 cGy to marrow-producing areas Surgery - Not specified Other - No other concurrent investigational agents - No other concurrent antileukemic agents - No concurrent treatment with any of the following: - Ketoconazole - Itraconazole - Voriconazole - Clarithromycin - Erythromycin - Phenytoin - Carbamazepine - Barbiturates - Cyclosporine - Pimozide - Warfarin - Grapefruit juice - Simvastatin - Lovastatin - Atorvastatin - No concurrent magnesium- or aluminum-containing antacids within 2 hours before or after tipifarnib administration |
Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | McMaster Children's Hospital at Hamilton Health Sciences | Hamilton | Ontario |
Canada | London Regional Cancer Program at London Health Sciences Centre | London | Ontario |
Lead Sponsor | Collaborator |
---|---|
University Health Network, Toronto | National Cancer Institute (NCI) |
Canada,
Brandwein JM, Leber BF, Howson-Jan K, Schimmer AD, Schuh AC, Gupta V, Yee KW, Wright J, Moore M, MacAlpine K, Minden MD; NCI CTEP Protocol 6670. A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously un — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose of tipifarnib when administered with cytarabine and daunorubicin | minimum of 30 days per treatment cycle | Yes | |
Primary | Toxicity | All cycles | Yes | |
Primary | Pharmacokinetics | Day 6 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |